Obesity-associated hypertension

Endocrine Hypertension: Underlying Mechanisms and Therapy

Volumn , Issue , 2013, Pages 251-288

  Uwaifo, Gabriel I ^a  

^a Department of Pathology   (United States)

Author keywords

Atrial natriuretic peptide system; Cortisol; Endothelin; Free fatty acids; Hyperinsulinemia; Hypertension; Leptin; Obesity; Obesity hypertension; Renin angiotensin aldosterone system; SNS overactivity

Indexed keywords

EID: 84870555466     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60761-548-4_13     Document Type: Chapter

References (292)

1. Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens. 2004;18:545-51.
2. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:686-95.
3. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA. 2004;291:2107-13.
4. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11-9.
5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.
6. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii; 1-253.
7. Francischetti EA, Genelhu VA. Obesity-hypertension: an ongoing pandemic. Int J Clin Pract. 2007;61:269-80.
8. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097-105.
9. Banegas JR, Lopez-Garcia E, Graciani A, et al. Relationship between obesity, hypertension and diabetes, and health-related quality of life among the elderly. Eur J Cardiovasc Prev Rehabil. 2007;14:456-62.
10. Aneja A, El-Atat F, McFarlane SI, Sowers JR. Hypertension and obesity. Recent Prog Horm Res. 2004;59:169-205.
11. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640-9.
12. Steyn K, Sliwa K, Hawken S, et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation. 2005;112:3554-61.
13. Larsson S, Alicja W. Epidemiology of obesity and diabetes. In: Mantzoros C, editor. Obesity and diabetics. Totowa: Humana; 2006. p. 15-30.
14. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40:441-7.
15. Virdis A, Ghiadoni L, Masi S, et al. Obesity in the childhood: a link to adult hypertension. Curr Pharm Des. 2009;15:1063-71.
16. Zhang L, Zhang WH, Zhang L, Wang PY. Prevalence of overweight/obesity and its associations with hypertension, diabetes, dyslipidemia, and metabolic syndrome: a survey in the suburban area of Beijing, 2007. Obes Facts. 2011;4(4):284-9.
17. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface. 2002;15:28-36.
18. Hansson L, Lloyd A, Anderson P, Kopp Z. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 2002;11:35-45.
19. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006;12:62-6.
20. Abstracts of the fourth international symposium on obesity and hypertension: genetics, molecular mechanisms, metabolic syndrome and cardiovascular risk. 27-29 October 2005, Berlin, Germany. Int J Obes (Lond). 2005;29 Suppl 3:S1-19.
21. Diaz ME. Hypertension and obesity. J Hum Hypertens. 2002;16 Suppl 1:S18-22.
22. El-Atat F, Aneja A, McFarlane S, Sowers J. Obesity and hypertension. Endocrinol Metab Clin North Am. 2003;32:823-54.
23. Faloia E, Giacchetti G, Mantero F. Obesity and hypertension. J Endocrinol Invest. 2000;23: 54-62.
24. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010;23:1170-8.
25. Kotchen TA. Obesity-related hypertension?: weighing the evidence. Hypertension. 2008;52:801-2.
26. Kurukulasuriya LR, Stas S, Lastra G, Manrique C, Sowers JR. Hypertension in obesity. Med Clin North Am. 2011;95(5):903-17.
27. Garrison RJ, Kannel WB, Stokes III J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16:235-51.
28. Okosun IS, Rotimi CN, Forrester TE, et al. Predictive value of abdominal obesity cut-off points for hypertension in blacks from west African and Caribbean island nations. Int J Obes Relat Metab Disord. 2000;24:180-6.
29. Harris MM, Stevens J, Thomas N, Schreiner P, Folsom AR. Associations of fat distribution and obesity with hypertension in a bi-ethnic population: the ARIC study. Atherosclerosis Risk in Communities Study. Obes Res. 2000;8:516-24.
30. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 1978;240:1607-10.
31. Heneghan HM, Meron-Eldar S, Brethauer SA, Schauer PR, Young JB. Effect of bariatric surgery on cardiovascular risk pro file. Am J Cardiol. 2011;108:1499-507.
32. Benraouane F, Litwin SE. Reductions in cardiovascular risk after bariatric surgery. Curr Opin Cardiol. 2011;26:555-61.
33. Johnson WD, Brashear MM, Gupta AK, Rood JC, Ryan DH. Incremental weight loss improves cardiometabolic risk in extremely obese adults. Am J Med. 2011;124(10):931-8.
34. Masuo K, Rakugi H, Ogihara T, Lambert GW. Different mechanisms in weight loss-induced blood pressure reduction between a calorie-restricted diet and exercise. Hypertens Res. 2012;35:41-7.
35. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-74.
36. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-9.
37. Cassano PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol. 1990;1:33-48.
38. Troisi RJ, Weiss ST, Segal MR, Cassano PA, Vokonas PS, Landsberg L. The relationship of body fat distribution to blood pressure in normotensive men: the normative aging study. Int J Obes. 1990;14:515-25.
39. Hayashi T, Boyko EJ, Leonetti DL, et al. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004;140:992-1000.
40. Canoy D, Luben R, Welch A, et al. Fat distribution, body mass index and blood pressure in 22,090 men and women in the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study. J Hypertens. 2004;22:2067-74.
41. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682-6.
42. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134:1-11.
43. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544-9.
44. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14:103S-15.
45. Haynes WG. Role of leptin in obesity-related hypertension. Exp Physiol. 2005;90:683-8.
46. Hall JE, da Silva AA, do Carmo JM, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285(23):17271-6.
47. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep. 2000;2:139-47.
48. Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003;12:195-200.
49. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625-33.
50. Pecly IM, Genelhu V, Francischetti EA. Renal functional reserve in obesity hypertension. Int J Clin Pract. 2006;60:1198-203.
51. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21-8.
52. Parati G. Obesity, hypertension and the sympathetic nervous system. J Hypertens. 2002;20:835-7.
53. Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125-33.
54. Wofford MR, Anderson Jr DC, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha-and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14:694-8.
55. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60:621-9.
56. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension. 1997;30:619-23.
57. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinology. 1997;138:3395-401.
58. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100:270-8.
59. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension. 2002;39:496-501.
60. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension. 2002;39:486-90.
61. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension. 2003;41:1072-9.
62. Rahmouni K. Obesity, sympathetic overdrive, and hypertension: the leptin connection. Hypertension. 2010;55:844-5.
63. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes. 2005;54:2012-8.
64. Umemura S, Nyui N, Tamura K, et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens. 1997;10:629-33.
65. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9-14.
66. Chan NN, Tong PC, Kong AP, Chan JC. Obesity hypertension: the rationale for renin-angiotensin system blockade. Hong Kong Med J. 2005;11:217-20.
67. Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 2007;10:1151-5.
68. Sibley S. Hypertension, obesity, and the renin-angiotensin system: a tale of tight associations. Minn Med. 2003;86:46-8.
69. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci. 1999;892:91-107.
70. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol. 1999;10 Suppl 12:S258-65.
71. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997;30:140-5.
72. Robles RG, Villa E, Santirso R, et al. Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens. 1993;6:1009-15.
73. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-62.
74. Barbato KBG, Martins RCV, Rodrigues MLG, Braga JU, Francischetti EA, Genelhu V. [Effects of greater-than-5% weight reduction on hemodynamic, metabolic and neuroendocrine pro files of grade I obese subjects]. Arq Bras Cardiol. 2006;87:12-21.
75. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43:518-24.
76. Goodfriend TL. Obesity, sleep apnea, aldosterone, and hypertension. Curr Hypertens Rep. 2008;10:222-6.
77. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211-6.
78. Di Guardo A, Profeta G, Crisafulli C, et al. Obstructive sleep apnoea in patients with obesity and hypertension. Br J Gen Pract. 2010;60:325-8.
79. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyper filtration. Hypertension. 2004;43:41-7.
80. Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin Nephrol. 2009;72:449-56.
81. Kotchen TA, Kotchen JM, Grim CE, Krishnaswami S, Kidambi S. Aldosterone and alterations of hypertension-related vascular function in African Americans. Am J Hypertens. 2009;22:319-24.
82. Kidambi S, Kotchen JM, Krishnaswami S, Grim CE, Kotchen TA. Aldosterone contributes to blood pressure variance and to likelihood of hypertension in normal-weight and overweight African Americans. Am J Hypertens. 2009;22:1303-8.
83. Peeke PM, Chrousos GP. Hypercortisolism and obesity. Ann N Y Acad Sci. 1995;771: 665-76.
84. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. 2002;87:3330-6.
85. Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism within super ficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf). 2006;65:81-7.
86. Wake DJ, Walker BR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity. Endocrine. 2006;29:101-8.
87. Bujalska IJ, Kumar S, Stewart PM. Does central obesity re flect "Cushing's disease of the omentum"? Lancet. 1997;349:1210-3.
88. Pastucha D, Talafa V, Malincikova J, et al. Obesity, hypertension and insulin resistance in childhood-a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154:77-81.
89. Bloomgarden ZT. Obesity, hypertension, and insulin resistance. Diabetes Care. 2002;25:2088-97.
90. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol. 2004;286:R803-13.
91. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-52.
92. Scherrer U, Owlya R, Trueb L. Sympathetic-nerve activity before and after resection of an insulinoma. N Engl J Med. 1996;335:1240-2.
93. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533-6.
94. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-74.
95. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-9.
96. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318-23.
97. Koch CA, Wofford M, Ayala AR, Pacak K. Overview of endocrine hypertension. Chapter 26 in Adrenal physiology and diseases (Chrousos GP, Section editor); 2009 http://www.endotext. org/adrenal/adrenal26/adrenalframe26.htm
98. Cardillo C, Kilcoyne CM, Cannon 3rd RO, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension. 2000;35:1237-41.
99. Cardillo C, Kilcoyne CM, Cannon III RO, Panza JA. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol. 2000;36:1483-8.
100. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension. 2004;43:36-40.
101. Campia U, Cardillo C, Panza JA. Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation. 2004;109:3191-5.
102. Jin JJ, Nakura J, Wu Z, et al. Association of endothelin-1 gene variant with hypertension. Hypertension. 2003;41:163-7.
103. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004;53:2060-6.
104. Bloom field GL, Sugerman HJ, Blocher CR, Gehr TW, Sica DA. Chronically increased intraabdominal pressure produces systemic hypertension in dogs. Int J Obes Relat Metab Disord. 2000;24:819-24.
105. Sugerman H, Windsor A, Bessos M, Wolfe L. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med. 1997;241:71-9.
106. Dwyer TM, Banks SA, Alonso-Galicia M, et al. Distribution of renal medullary hyaluronan in lean and obese rabbits. Kidney Int. 2000;58:721-9.
107. Kurukulasuriya LR, Stas S, Lastra G, Manrique C, Sowers JR. Hypertension in obesity. Endocrinol Metab Clin North Am. 2008;37:647-62; ix.
108. Hall JE, Brands MW, Henegar JR, Shek EW. Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol. 1998;25:58-64.
109. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498-509.
110. Redon J. Hypertension in obesity. Nutr Metab Cardiovasc Dis. 2001;11:344-53.
111. Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension in obesity. Vasc Health Risk Manag. 2006;2:163-9.
112. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002;324:127-37.
113. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular alpha-adrenergic sensitivity. Hypertension. 1995;25:774-8.
114. Grekin RJ, Dumont CJ, Vollmer AP, Watts SW, Webb RC. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol. 1997;273:R324-30.
115. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230-9.
116. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-12.
117. Tan MS, Chang SY, Chang DM, Tsai JC, Lee YJ. Association of resistin gene 3 ¢ -untranslated region +62G->A polymorphism with type 2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metab. 2003;88:1258-63.
118. Zhang J, Qin Y, Zheng X, et al. [The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure]. Zhonghua Yi Xue Za Zhi. 2002;82:1609-12.
119. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992;10:1111-4.
120. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens. 1992;10:907-12.
121. Ogawa Y, Nakao K, Nakagawa O, et al. Human C-type natriuretic peptide. Characterization of the gene and peptide. Hypertension. 1992;19:809-13.
122. Komatsu Y, Nakao K, Itoh H, Suga S, Ogawa Y, Imura H. Vascular natriuretic peptide. Lancet. 1992;340:622.
123. Melo LG, Veress AT, Chong CK, Pang SC, Flynn TG, Sonnenberg H. Salt-sensitive hypertension in ANP knockout mice: potential role of abnormal plasma renin activity. Am J Physiol. 1998;274:R255-61.
124. Melo LG, Pang SC, Ackermann U. Atrial natriuretic peptide: regulator of chronic arterial blood pressure. News Physiol Sci. 2000;15:143-9.
125. Melo LG, Steinhelper ME, Pang SC, Tse Y, Ackermann U. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics. 2000;3:45-58.
126. Dessi-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens. 1997;15:1695-9.
127. Dessi-Fulgheri P, Sarzani R, Serenelli M, et al. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension. 1999;33:658-62.
128. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension. 1994;23:120-4.
129. Sarzani R, Dessi-Fulgheri P, Salvi F, et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens. 1999;17:1301-5.
130. Abate NI, Mansour YH, Tuncel M, et al. Overweight and sympathetic overactivity in black Americans. Hypertension. 2001;38:379-83.
131. Berchtold P, Jorgens V, Finke C, Berger M. Epidemiology of obesity and hypertension. Int J Obes. 1981;5 Suppl 1:1-7.
132. Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension. 2000;36:531-7.
133. Castro JP, El-Atat FA, McFarlane SI, Aneja A, Sowers JR. Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep. 2003;5:393-401.
134. Good D, Morse SA, Ventura HO, Reisin E. Obesity, hypertension, and the heart. J Cardiometab Syndr. 2008;3:168-72.
135. Pilz B, Brasen JH, Schneider W, Luft FC. Obesity and hypertension-induced restrictive cardiomyopathy: a harbinger of things to come. Hypertension. 2004;43:911-7.
136. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality-results from the Framingham Study. Cardiology. 1992;81:291-8.
137. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844-50.
138. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952-8.
139. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-74.
140. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. In flammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int. 2000;58:1703-10.
141. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical in flammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-7.
142. Das UN. Is obesity an in flammatory condition? Nutrition. 2001;17:953-66.
143. Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother. 2010;44:1207-21.
144. McCarty MF. Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. Med Hypotheses. 2010;75:276-81.
145. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia. 2009;52:385-93.
146. Fleischman A, Shoelson SE, Bernier R, Gold fine AB. Salsalate improves glycemia and in flammatory parameters in obese young adults. Diabetes Care. 2008;31:289-94.
147. Gold fine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152:346-57.
148. Konstantinides S, Schafer K, Loskutoff DJ. The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity. Ann N Y Acad Sci. 2001;947:134-41; discussion 141-2.
149. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001;108:1533-40.
150. Terzolo M, Reimondo G, Bovio S, Angeli A. Subclinical Cushing's syndrome. Pituitary. 2004;7:217-23.
151. Terzolo M, Bovio S, Pia A, et al. Subclinical Cushing's syndrome. Arq Bras Endocrinol Metabol. 2007;51:1272-9.
152. Mazzuco TL, Bourdeau I, Lacroix A. Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2009;16:203-10.
153. Gagliardi L, Torpy DJ. Subclinical Cushing's syndrome in adrenal incidentaloma: a common problem or an artefact of current diagnostic testing? Clin Endocrinol (Oxf). 2010; 72:277-8.
154. Terzolo M, Pia A, Ali A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87:998-1003.
155. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000;85:1440-8.
156. Baguet JP, Narkiewicz K, Mallion JM. Update on hypertension management: obstructive sleep apnea and hypertension. J Hypertens. 2006;24:205-8.
157. Tu fik S, Santos-Silva R, Taddei JA, Bittencourt LR. Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study. Sleep Med. 2010;11:441-6.
158. Shah N, Roux F. The relationship of obesity and obstructive sleep apnea. Clin Chest Med. 2009;30:455-65; vii.
159. de Sousa AG, Cercato C, Mancini MC, Halpern A. Obesity and obstructive sleep apneahypopnea syndrome. Obes Rev. 2008;9:340-54.
160. Zhang XL. [Obstructive sleep apnea hypopnea and metabolic syndromes]. Zhonghua Jie He He Hu Xi Za Zhi. 2007;30:891-3.
161. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284:3015-21.
162. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleepdisordered breathing and hypertension. N Engl J Med. 2000;342:1378-84.
163. Morrell MJ, Finn L, Kim H, Peppard PE, Badr MS, Young T. Sleep fragmentation, awake blood pressure, and sleep-disordered breathing in a population-based study. Am J Respir Crit Care Med. 2000;162:2091-6.
164. Young T, Peppard P. Sleep-disordered breathing and cardiovascular disease: epidemiologic evidence for a relationship. Sleep. 2000;23 Suppl 4:S122-6.
165. Bausmer U, Gouveris H, Selivanova O, Goepel B, Mann W. Correlation of the Epworth Sleepiness Scale with respiratory sleep parameters in patients with sleep-related breathing disorders and upper airway pathology. Eur Arch Otorhinolaryngol. 2010;267:1645-8.
166. Jacobs CK, Coffey J. Clinical inquiries. Sleep apnea in adults: how accurate is clinical prediction? J Fam Pract. 2009;58:327-8.
167. Dimsdale JE, Coy T, Ziegler MG, Ancoli-Israel S, Clausen J. The effect of sleep apnea on plasma and urinary catecholamines. Sleep. 1995;18:377-81.
168. Narkiewicz K, Pesek CA, Kato M, Phillips BG, Davison DE, Somers VK. Barore flex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. Hypertension. 1998;32:1039-43.
169. Robinson GV, Stradling JR, Davies RJ. Sleep. 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension. Thorax. 2004;59:1089-94.
170. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax. 2004;59:777-82.
171. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxia-in fluence of chemoreceptors and sympathetic nervous system. J Hypertens. 1997;15:1593-603.
172. Bao G, Metreveli N, Li R, Taylor A, Fletcher EC. Blood pressure response to chronic episodic hypoxia: role of the sympathetic nervous system. J Appl Physiol. 1997;83: 95-101.
173. Bao G, Randhawa PM, Fletcher EC. Acute blood pressure elevation during repetitive hypocapnic and eucapnic hypoxia in rats. J Appl Physiol. 1997;82:1071-8.
174. Baguet JP, Erdine S, Mallion JM. European Society of Hypertension Scienti fic Newsletter: update on hypertension management: hypertension and dysrhythmias. J Hypertens. 2006; 24:409-11.
175. Kato M, Roberts-Thomson P, Phillips BG, et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation. 2000;102:2607-10.
176. Duchna HW, Stoohs R, Guilleminault C, Christine Anspach M, Schultze-Werninghaus G, Orth M. Vascular endothelial dysfunction in patients with mild obstructive sleep apnea syndrome. Wien Med Wochenschr. 2006;156:596-604.
177. Duchna HW, Orth M, Schultze-Werninghaus G, Guilleminault C, Stoohs RA. Antihypertensive treatment and endothelium-dependent venodilation in sleep-disordered breathing. Sleep Breath. 2006;10:115-22.
178. Gjorup PH, Sadauskiene L, Wessels J, Nyvad O, Strunge B, Pedersen EB. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens. 2007;20:44-52.
179. Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999;17:61-6.
180. Moller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens. 2003;16:274-80.
181. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009;51:371-80.
182. Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep. 2008;10:496-503.
183. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125:112-7.
184. Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis. 2006;48:387-96.
185. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension. 1999;34:309-14.
186. Masserini B, Morpurgo PS, Donadio F, et al. Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest. 2006;29:700-5.
187. Zhang XL, Yin KS, Wang H, Su S. Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration. 2006;73:73-7.
188. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf). 2006;64:12-9.
189. Zhang XL, Yin KS, Li C, Jia EZ, Li YQ, Gao ZF. Effect of continuous positive airway pressure treatment on serum adiponectin level and mean arterial pressure in male patients with obstructive sleep apnea syndrome. Chin Med J (Engl). 2007;120:1477-81.
190. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992;152:131-6.
191. Wofford MR, Smith G, Minor DS. The treatment of hypertension in obese patients. Curr Hypertens Rep. 2008;10:143-50.
192. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
193. Reisin E, Hutchinson HG. Obesity-hypertension:the effects on cardiovascular and renal systems-the therapeutic approach. In: Oparil S, Weber MA, editors. Hypertension. Philadelphia: W.B. Saunders; 1999. p. 206-10.
194. Battling Obesity & Hypertension. Does the DASH diet really reduce blood pressure? AWHONN Lifelines. 2002;6:21-3.
195. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-24.
196. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978;298:1-6.
197. Reisin E, Frohlich ED. Effects of weight reduction on arterial pressure. J Chronic Dis. 1982;35:887-91.
198. Kannel WB, Brand N, Skinner Jr JJ, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967;67:48-59.
199. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA. 1992;267: 1213-20.
200. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839-46.
201. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. In fluence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-84.
202. Harsha DW, Bray GA. Weight loss and blood pressure control (Pro). Hypertension. 2008;51:1420-5; discussion 1425.
203. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3-10.
204. Vollmer WM, Sacks FM, Svetkey LP. New insights into the effects on blood pressure of diets low in salt and high in fruits and vegetables and low-fat dairy products. Curr Control Trials Cardiovasc Med. 2001;2:71-4.
205. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001;135:1019-28.
206. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27: 481-90.
207. Hoffmann IS, Al fieri AB, Cubeddu LX. Salt-resistant and salt-sensitive phenotypes determine the sensitivity of blood pressure to weight loss in overweight/obese patients. J Clin Hypertens (Greenwich). 2008;10:355-61.
208. Gillum RF, Prineas RJ, Jeffery RW, et al. Nonpharmacologic therapy of hypertension: the independent effects of weight reduction and sodium restriction in overweight borderline hypertensive patients. Am Heart J. 1983;105:128-33.
209. Jeffery RW, Gillum R, Gerber WM, Jacobs D, Elmer PJ, Prineas RJ. Weight and sodium reduction for the prevention of hypertension: a comparison of group treatment and individual counseling. Am J Public Health. 1983;73:691-3.
210. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl III HW, Blair SN. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA. 1999;281:327-34.
211. Andersen RE, Wadden TA, Bartlett SJ, Zemel B, Verde TJ, Franckowiak SC. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial. JAMA. 1999;281:335-40.
212. Fagard R, Bielen E, Hespel P. Physical exercise in hypertension. In: Laralaragh J, Renner B, editors. Hypertension pathophysiology, diagnosis and management. New York: Raven Press; 1990. p. 1985-8.
213. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a metaanalysis of randomized, controlled trials. Ann Intern Med. 2002;136:493-503.
214. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arterioscler Thromb Vasc Biol. 2006;26:2186-91.
215. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scienti fic statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82-96.
216. Trapp EG, Chisholm DJ, Freund J, Boutcher SH. The effects of high-intensity intermittent exercise training on fat loss and fasting insulin levels of young women. Int J Obes (Lond). 2008;32:684-91.
217. Institute of Medicine. Dietary reference intakes for energy, carbohydrates, fibre, fat, fatty acids, cholesterol and protein and amino acids. 2002.
218. Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am. 2009;93:733-51.
219. Fuchs FD. Vascular effects of alcoholic beverages: is it only alcohol that matters? Hypertension. 2005;45:851-2.
220. Gordon T, Kannel WB. Drinking habits and cardiovascular disease: the Framingham Study. Am Heart J. 1983;105:667-73.
221. Gordon T, Kannel WB. Drinking and its relation to smoking, BP, blood lipids, and uric acid. The Framingham study. Arch Intern Med. 1983;143:1366-74.
222. Klatsky AL, Friedman GD, Siegelaub AB, Gerard MJ. Alcohol consumption among white, black, or oriental men and women: Kaiser-Permanente multiphasic health examination data. Am J Epidemiol. 1977;105:311-23.
223. Klatsky AL, Friedman GD, Siegelaub AB, Gerard MJ. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med. 1977;296:1194-200.
224. Puddey IB, Parker M, Beilin LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension. 1992; 20:533-41.
225. Parker M, Puddey IB, Beilin LJ, Vandongen R. Two-way factorial study of alcohol and salt restriction in treated hypertensive men. Hypertension. 1990;16:398-406.
226. Klatsky AL, Gunderson E. Alcohol and hypertension: a review. J Am Soc Hypertens. 2008;2:307-17.
227. Boutelle KN, Kirschenbaum DS. Further support for consistent self-monitoring as a vital component of successful weight control. Obes Res. 1998;6:219-24.
228. Schouten R, Wiryasaputra DC, van Dielen FM, van Gemert WG, Greve JW. Long-term results of bariatric restrictive procedures: a prospective study. Obes Surg. 2010;20: 1617-26.
229. Abeles D, Shikora SA. Bariatric surgery: current concepts and future directions. Aesthet Surg J. 2008;28:79-84.
230. Sebastian JL. Bariatric surgery and work-up of the massive weight loss patient. Clin Plast Surg. 2008;35:11-26.
231. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761-9.
232. Reisin E, Tuck ML. Obesity-associated hypertension: hypothesized link between etiology and selection of therapy. Blood Press Monit. 1999;4 Suppl 1:S23-6.
233. Richards RJ, Thakur V, Reisin E. Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment. J Hum Hypertens. 1996;10 Suppl 3:S59-64.
234. Masuo K, Mikami H, Ogihara T, Tuck ML. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001;14:530-8.
235. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005;46:137-43.
236. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-9.
237. Parving HH, Brenner BM, Cooper ME, et al. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. Ugeskr Laeger. 2001; 163:5514-9.
238. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
239. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31.
240. Cohn JN, Julius S, Neutel J, et al. Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. Am J Hypertens. 2004;17:134-8.
241. Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich). 2004;6:10-7.
242. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
243. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-9.
244. Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation. 1959;20:1028-36.
245. Weir MR, Reisin E, Falkner B, Hutchinson HG, Sha L, Tuck ML. Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. Am J Hypertens. 1998;11:914-20.
246. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-97.
247. Lithell H. Hypertension and hyperlipidemia. A review. Am J Hypertens. 1993;6:303S-8.
248. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-12.
249. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro flumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
250. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-53.
251. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000;342:969-70.
252. MacMahon SW, Macdonald GJ, Bernstein L, Andrews G, Blacket RB. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet. 1985;1:1233-6.
253. MacMahon SW, Macdonald GJ, Bernstein L, Andrews G, Blacket RB. A randomized controlled trial of weight reduction and metoprolol in the treatment of hypertension in young overweight patients. Clin Exp Pharmacol Physiol. 1985;12:267-71.
254. Fagerberg B, Berglund A, Andersson OK, Berglund G, Wikstrand J. Cardiovascular effects of weight reduction versus antihypertensive drug treatment: a comparative, randomized, 1-year study of obese men with mild hypertension. J Hypertens. 1991;9:431-9.
255. Sara fidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8:351-6; quiz 357-8.
256. Sara fidis PA, Bakris GL. Are beta blockers passe for the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8:239-40.
257. Sara fidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99:431-6.
258. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-36.
259. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351: 1755-62.
260. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-64.
261. Tuck ML, Bravo EL, Krakoff LR, Friedman CP. Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension Study Group. Am J Hypertens. 1990;3:333S-41.
262. Krakoff LR, Bravo EL, Tuck ML, Friedman CP. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension (MATH) Study Group. Am J Hypertens. 1990;3:318S-25.
263. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65: 1991-2002.
264. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283:1967-75.
265. Scheen AJ. Cardiovascular risk-bene fit pro file of sibutramine. Am J Cardiovasc Drugs. 2010;10:321-34.
266. Curfman GD, Morrissey S, Drazen JM. Sibutramine-another flawed diet pill. N Engl J Med. 2010;363:972-4.
267. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-17.
268. Galhardo J, Davis N, Matthai S, Shield JP. European Medicines Agency withdrawal for sibutramine. Arch Dis Child. 2010;95:856.
269. Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Saf. 2010;33:605-13.
270. Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824.
271. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005;45:1035-41.
272. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8:iii-iv; 1-182.
273. Aucott L, Poobalan A, Smith WC, et al. Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes-a systematic review. Diabetes Obes Metab. 2004;6:85-94.
274. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-34.
275. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-75.
276. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Ef ficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-72.
277. Weaver TE, Chasens ER, Arora S. Moda finil improves functional outcomes in patients with residual excessive sleepiness associated with CPAP treatment. J Clin Sleep Med. 2009;5:499-505.
278. Bogan RK. Armoda finil in the treatment of excessive sleepiness. Expert Opin Pharmacother. 2010;11:993-1002.
279. Williams SC, Marshall NS, Kennerson M, Rogers NL, Liu PY, Grunstein RR. Moda finil effects during acute continuous positive airway pressure withdrawal: a randomized crossover double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2010;181:825-31.
280. Ballard RD. Management of patients with obstructive sleep apnea. J Fam Pract. 2008; 57:S24-30.
281. Valentino RM, Foldvary-Schaefer N. Moda finil in the treatment of excessive daytime sleepiness. Cleve Clin J Med. 2007;74(561-6):568-71.
282. Abad VC, Guilleminault C. Pharmacological management of sleep apnoea. Expert Opin Pharmacother. 2006;7:11-23.
283. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281-4.
284. Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13:79-84.
285. Nunes DM, Mota RM, Machado MO, Pereira ED, Bruin VM, Bruin PF. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res. 2008;41:926-31.
286. Tsaoussoglou M, Bixler EO, Calhoun S, Chrousos GP, Sauder K, Vgontzas AN. Sleepdisordered breathing in obese children is associated with prevalent excessive daytime sleepiness, in flammation, and metabolic abnormalities. J Clin Endocrinol Metab. 2010; 95(1):143-50.
287. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-7.
288. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Collins B, Basta M, Peiovic S, Chrousos GP. Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest. 2008;38(8):585-95.
289. Dorresteijn JA, Visseren FL, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev. 2012;13:17-26.
290. Vasylyeva TL, Chennasamudram SP, Okogbo ME. Can we predict hypertension among preterm children ? Clin Pediatr. 2011;50(10):936-42.
291. Humphreys MH. The brain splits obesity and hypertension. Nat Med. 2011;17(7):782-3.
292. Purkayastha S, Zhang G, Cai D. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kappaB. Nat Med. 2011;17(7):883-7.